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Attention Deficit Hyperactivity Disorder in Appalachia: proposed
methods to analyze and solve social and medical issues surrounding the
disorder

Alexis Prillhart
The University of Tennessee, Knoxville

Introduction to Appalachia, Its Health Disparities, and Overall Reasons
They Exist
The Appalachian Regional Commission (ARC) defines the Appalachian Region as,
“The 205,000-square-mile region that follows the spine of the Appalachian Mountains
from southern New York to northern Mississippi. It includes all of West Virginia and
parts of 12 other states: Alabama, Georgia, Kentucky, Maryland, Mississippi, New York,
North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia.” The
Appalachian Region is home to over 25 million people (“Appalachian Region”, 2015).
Appalachian people hold a culture of their own, a culture that not many outsiders know
much about. In fact, only recently, due to technology and communication improvements,
has information about this unique culture started to emerge. Appalachia is historically
known as a region that is lacking in healthcare and home to many unhealthy inhabitants.
Currently, many studies are emerging, focusing on improving healthcare and
understanding the environmental, social, and cultural distinctions in the region that may
lead to limitations (Couto, 2012). There are several broad factors that may contribute to
the unhealthiness of the region as a whole including poverty, rurality, and the various
cultures and beliefs of the region.
There are several factors that may lead to disparities in healthcare. One main factor
in the lack of healthcare may be contributed to poverty. Poverty, although not evenly
distributed throughout the region, is rampant. The ARC reports that from 2009-2013 the
Appalachia region had a poverty rate of 17.0%, compared to the national poverty rate of
15.4% (“Poverty Rates in Appalachia”, 2014). As stated, poverty is not universal, and is

usually found in clusters throughout. Poverty may prevent Appalachians from seeking out
healthcare due to affordability and even transportation costs (Couto, 2012).
In addition to poverty, rurality may also prevent Appalachians from receiving
healthcare. In the past several years Appalachia has transformed from a rural to an
urbanized region. However, there are still several areas, primarily in central Appalachia,
that are mostly rural. Many Appalachians consider rurality a stereotype, but it is reality
that more rural areas do not have healthcare access close by. Hospitals and doctors'
offices are more concentrated in metro, urban areas than in rural regions of Appalachia.
Lack of transportation and money to travel may impede the possibility of seeking a
professional’s health advice (Couto, 2012).
Lastly, and more broadly, the social culture of the region may have an impact of the
ability to receive healthcare. Appalachians are hesitant to describe their culture as a
whole entity, as each area in the region has distinct cultural differences. They are also
afraid that stereotypes may be derived. However, there are a few broad topics that are
mostly true for the entire region (Couto, 2012). Appalachian people consider taking care
of oneself and family a priority, meaning they will put taking care of the family through
work before taking the time to visit a health professional (Gessert, 2015). It is this
independent focus that leads to many healthcare providers to discriminate. Providers may
be likely to lackadaisically treat the patient due to the belief the patient will not listen
them and will disagree on the treatment (Puhl, 2010). Appalachians generally do not trust
with ease, and are hesitant to trust people, like doctors, that live a different and more
educated lifestyle. They may also see the help from doctors as a charity, and thus, be less
receptive of advice (Beringer, 2006).

Another aspect of Appalachian social culture is family. Family plays an important
role in the culture and health of Appalachians. The Appalachian family is more than the
nuclear family; it includes the parents, children, grandparents, and the parents’ siblings
and children. In a broader sense it can even include the community. Children are usually
taken care of by grandparents and other family members instead of attending daycare
while their parents work. This leaves the family in charge of noticing any healthcare
ailments in the child. The family also depends on each other to raise money to attend
healthcare visits annually. This leads back to the discussion on poverty in the family
(Welch, 2014). The family also usually shares traditions and faith. The Appalachian
region is known for having strong ties to religion and faith. While religion is not
universal in the region, it does have an impact in some areas pertaining to healthcare. The
Appalachian people are more likely to believe in faith-based fatalism, or the concept that
illness is a part of God’s plan and He will heal the patient. This thought process might
lead to Appalachians to believe that all illness is “in God’s hands” and medication is not
necessary (Welch, 2011). Healthcare providers must be aware of religious beliefs in an
area as they can drastically affect how a patient acts towards taking medication and even
attending appointments.
The social, economic, and cultural aspects of the Appalachian region are very broad
and specific to the area. It is hard to account for every factor, and even harder to
determine which ones to include, when studying how they may impact the healthcare in a
specific Appalachian city. Each Appalachian town must cater to its own social and
cultural beliefs when developing a healthcare plan. Poverty, the urbanization of the area,
and the cultural attitudes of the area are among the factors that must be accounted for. As

stated, these are broad attitudes of the Appalachian people, and do not apply to the whole
population. However, these attitudes are important to note as crafting a health plan to
include them may improve communication, education, and overall health in the
Appalachian region.
Potential Reasons for Health Disparities in Appalachian Pediatric Patients
Not much is known about Appalachia as a whole, and even less is known about the
children that reside in the region. Social scientists and healthcare providers are just
beginning to develop systems to help the region, but not many of these developments
focus on the health of the Appalachian child. The Appalachian lifestyle can have an
affect on the health of youth in the region, as they are dependent on the family and the
overall system to meet their needs. While the previously mentioned aspects of the region
will affect everyone in the region, there are a few more characteristics of Appalachia that
affect youth more specifically in healthcare including lack of managed care, education
and social distance, and the social environment of the child.
Managed care is a health system that is designed to deliver quality health care at a
reduced cost and high availability. More simply stated, managed care is the
implementation of health insurance programs. There is a severe lack of managed care in
the Appalachian region. Managed care rates are less than 15% in half of the states in the
Appalachia region, and only four states have rates above 25%, which is still below the
national average. Insurance plans are held by 75% of Appalachian children, significantly
lower than the 85% of non-Appalachian children that possess insurance plans (“Child
Well-being Survey”, 2011). Low rates of managed care in the region has a major impact
on the healthcare of pediatric patients. Lack of insurance may lead to use of emergency

room visits as the primary or source of healthcare. Parents that do not have insurance
plans are less likely to have a primary care physician for their child, meaning the child
will usually not participate in regularly scheduled appointments (Couto, 2012). Parents
that do not have insurance plans are often low-income, which will have other
implications to be discussed shortly. Lack of managed care will also lead restrictions on
access to preventative and educational resources. Without managed care plans
Appalachian children are less likely to receive care early on in life. They are also less
likely to grow up attending regular appointments; this will likely carry over into adult
life. The decreased levels of insurance plans is lessening the opportunities of healthcare
for Appalachian children, and negatively impacting their health.
Low education levels in the Appalachian region may negatively impact the
healthcare of pediatric patients in the region. In a consensus report in 2010 the ARC
reported that 17.1% of the Appalachian population has no high school diploma, while in
non-Appalachian regions, only 15% of residents do not have a high school diploma (“The
Appalachian Region: A Data Overview from the 2006-2010 American Community
Survey”, 2011). This statistic shows that Appalachians are not completing high school
studies comparable to non-Appalachians, and thus will not continue on to receive
secondary education. Uneducated populations are more likely to become ill and develop
disease than educated populations. They are also less likely to notice and understand the
severity when an illness arises, especially mental illness, and seek medical attention when
needed (Turiano, 2014). Parents lacking education may not understand the complex
medical terminology that is utilized to explain the health of their child and the importance
of basic medical care, such as vaccinations and how to understand and read prescriptions.

Part of this issue may arise from the social distance that is created among educated health
professionals and uneducated patients. A language barrier often exists, leading to
confusion on the patients’ end. This is partly due to an education gap between the health
practitioner and the patient, but is also caused by the numerous doctors that are from
outside Appalachia, who are unfamiliar with the colloquialisms of the region
(Hutson,2007). The education gap and language barrier both add confusion to a parent,
leading to hesitation when seeking care for their child. Uneducated parents are less likely
to take their children to doctors’ appointments than more educated parents. This may be
due to the fact that lack of education usually leads to career paths that do not produce a
great income and lead to increased hours on the clock (Cutler, 2006). Many parents in the
Appalachian region are working long hours to provide for their family and they do not
have the time, resources, such as income and transportation, or the knowledge to
understand general health and assure their child is receiving medical care on a scheduled
basis.
Although it is impossible to define the social environment of Appalachian children
as a whole, social trends can be determined to aid in understanding the health of
Appalachian children. The Child Well-Being Survey, conducted by the Cincinnati
Children’s Hospital, reported that Appalachian children are more likely to live in singleparent homes than non-Appalachian children (2011). Single-parent families may find
difficulty in finding the time and resources to attend health appointments. Children in
single-parent homes are likely to experience less health care than other children. Parents
of Appalachian children are more likely to work full time and longer hours than parents
outside the region (“Child Well-Being Survey”, 2011). Because of this, Appalachian

children often possess part time caregivers. At a young age the children are watched by
other family members, and are not socialized with children outside the family unit. The
lack of a parental figure increases the independence in many Appalachian children, but
often leads to increased behavioral issues and defiance. As a child matures, the absence
of parental supervision increases the chances of alcohol and substance abuse (Couto,
2012). Substance abuse is another issue that Appalachian children encounter often.
Alcohol and drug abuse is extremely common in rural Appalachia, and often children
mimic abuse behaviors they learn from observing parental actions. Sometimes parents
even take advantage of access to their child’s medications, and the child does not receive
the medication they are prescribed (Zhang, 2008). The social environment of a child can
lead to a decrease in the quality of the healthcare he receives. Providers should pay
special attention to the social environment of the child, which revolves mainly around
parental involvement and quality of care, and adjust interactions to account for the
environment the child faces on a day to day basis.
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ADHD in Appalachia and Tennessee
Cases of ADHD in the southern and Appalachian regions of the United States are
rampant. The Appalachian region has high percentages of children diagnosed with
ADHD between the ages of 4-17. Out of the 12 Appalachian states 7 had 13.1% or more
parents report their child had been diagnosed with ADHD. The other 5 states had 11.1%13.0% of parents report a child with an ADHD diagnosis (Figure 1). The percentage of
youth taking medication for ADHD is also high in the Appalachian region as a whole.
Four of the 12 states have 5.1%-7.0% of youth taking ADHD medications, and another 4
states have 7.1-9.0%. Of the 6 states in the US that have a 9.1% or greater youth
population on ADHD medications, 2, Kentucky and North Carolina, are Appalachian
states (Figure 2). It is clear through this data that the Appalachian region has a high
amount of ADHD cases and it is important for further research to understand why it is so
prevalent in these areas.
Tennessee has exceptionally high rates of diagnosed and medicated pediatric
ADHD patients. According to the National Survey of Children’s Health conducted by the
CDC in 2011, 15.2% of parents in Tennessee reported that a health care provider had told
them their child had ADHD while the average in the U.S. was 11.0% of parents. 11.1%
of parents in Tennessee reported their child currently has ADHD compared to an average
of 8.8% in the US. The national average for pediatric patients taking medication for
ADHD is 6.1%, and the report shows that 8.5% of Tennessee parents stated that their
children were on medication for ADHD (State Profile: Tennessee, 2014).
Medications are also dispensed at a high rate in Tennessee, with little to no behavior
management in place. In the same survey, when parents were asked if their child had

taken ADHD medication in the past week, nationally 74% of parents reported their child
had. 80% of Tennessee parents reported their child had taken ADHD medications in the
past week; this placed Tennessee as the 12th highest state out of all states and D.C.. The
survey also asked parents if their child had received behavior therapy, such as in class
aid, peer counseling, or classroom management therapy, in the past year. Nationally 44%
of parents reported their child had received behavior therapy. Only 33% of children in
Tennessee had received behavior therapy; this was the lowest average nationally ranking
Tennessee 51st out of all states and D.C. for patients receiving behavior therapy. Lastly
the survey asked parents if their child had taken medication in the last week and received
behavior therapy in the last year. The national average was 31%, and Tennessee was once
again ranked 51st with an average of 22% (State Profile: ADHD, 2014).
These findings do not focus on the Appalachian region of Tennessee specifically, in
which this study aims to focus on, but instead shows the data for the state as a whole.
Very little data exists for Appalachian Tennessee health, and even less exists for mental
health in Appalachia as a whole. However, this data does show that Tennessee overall has
a high amount of ADHD patients and medication treatment. The data shows the
importance of implementing more studies into ADHD in the Appalachian Tennessee
region to combat this widespread disorder. Further studies should focus on why ADHD is
a problem in Tennessee compared to other states and why medications are the preferred
treatment method. This research project hopes to understand how factors in the
Appalachian region lead to increased diagnosis and medication treatment for ADHD in
pediatric patients throughout the region and specifically in the state of Tennessee.

Figure 1. Percent of Youth 4-17 Ever Diagnosed with Attention-Deficit/Hyperactivity
Disorder by State: National Survey of Children's Health. Reprinted from Centers
for Disease Control and Prevention. Retrieved April 15, 2016, from
http://www.cdc.gov/ncbddd/adhd/prevalence.html

Figure 2. Percent of Youth Aged 4-17 Years Currently Taking Medication for ADHD by
State: National Survey of Children's Health. Reprinted from Centers for Disease
Control and Prevention. Retrieved April 15, 2016, from,
http://www.cdc.gov/ncddd/adhd/medicated.html
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Overview of ADHD
Attention Deficit Hyperactivity Disorder (ADHD) has likely been permeating
society since the beginning of time, although it was not until 1998 that the United States
recognized it as genuine medical condition (Moghadam, 2006). ADHD, often referred to
by its former name Attention Deficit Disorder (ADD), is a complex mental and
neurodevelopmental disorder that is often characterized by the inability to focus and
avoid distractions appropriate to the age level of the person (Adler, 2015). Impulsiveness
is also a common trait in ADHD patients, and this often leads to the inability to control
temptations. ADHD was once viewed as a childhood illness, but is now seen as a disorder
that can impact all age groups (McGough, 2014). While inattentiveness in a specific
environment, such as church, school, or home, is a common element of childhood,
children diagnosed with ADHD usually have difficulty with attentiveness in all
environments (Moghadam, 2006). In recent years, focus on ADHD has increased and led
to the development of a more accurate working definition. Medical professionals now
recognize ADHD as a developmental disorder of the brain, instead of a strictly behavioral
disorder (Brown, 2013).
As stated, ADHD is a severely complex disorder. No two patients exhibit the same
complications and issues, and currently medical professionals are recognizing the
importance of individuality in this condition. There are three forms of ADHD,
inattentiveness, hyperactivity, and a combinational form. Patients can exhibit inattentive
behavior with no hyperactivity, and others will exhibit hyperactivity but will still have the
ability to focus on assignments they are interested in. ADHD patients with a combination

of the first two forms will have an exceptionally difficult time focusing and managing
restless behavior (Hinshaw, 2016).
Patients with ADHD suffer with two types of cognitive impairments: working
memory and executive functions. Working memory is simply the ability to remember and
act on several components at once. The ability to turn on the sink and remember why it
was turned on is a fine example of working memory and how an individual might use it
to complete simple daily tasks. The individuality of ADHD is mostly represented by the
executive function impairment in the patient. Executive functions are the functions of the
brain that plan, prioritize, strategize, and act. Lack of these functions may be why ADHD
children arrive late to appointments, cannot keep track of assignments, and have social
difficulty (Hinshaw, 2016). Lack of executive functions is not a lack of intelligence, but it
does have everything to do with independence and self-care for ADHD patients.
Executive functions may be impaired throughout a person’s life through head trauma
accidents or Alzheimer’s, but ADHD patients have a developmental disorder of executive
functions, meaning they simply never form. Some executive functions do develop and
others do not, and that is why ADHD patients are so strikingly different and why
treatment must start to cater to the individual’s needs and interests (Lezak, 2004).
Causes of ADHD
The cause of ADHD has been debated since the illness was discovered. Over time
the medical and scientific community has determined that the cause of ADHD is
biological, however, social and environmental factors may fuel negative or positive
effects of ADHD. The basic cause of ADHD comes down to a small neurotransmitter
called dopamine. Dopamine travels across synapses in the brain, allowing the brain to

decipher messages to produce functions. Too much dopamine can cause a manic state
while too little can paralyze a person. Patients with ADHD either make too much of it or
do not have enough receptors to use it efficiently. Norepinephrine is another
neurotransmitter that is responsible for causing the impulsivity issues in patients with
ADHD, however, dopamine is the more largely studied neurotransmitter (Hinshaw,
2016).
While the above is the basic physiological cause of ADHD, many still wonder why
this occurs. This section of the introduction aims to discuss the biological causes and the
social and environmental risks that may impact a patient with ADHD in a negative or
positive manner.
Genetics
Twenty to thirty percent of children diagnosed with ADHD have at least one other
affected family member (McGough, 2014). There is no specific gene that is related to the
inheritance of ADHD, but there may be as many as 50-100 alleles involved in influencing
how the brain reads signals (Hinshaw, 2016). One of the most studied alleles is the
DRD4-7 allele, which may cause the brain to develop fewer dopamine receptors.
Dopamine is a neurotransmitter that causes excitement and stimulation. The lack of
dopamine receptors causes the brain to feel tired and boredom to ensue, and in response
the patient’s body begins to act fidgety and hyperactive to escape the lack of stimulation
(Faraone, 2005).
While genetics may play a heavy role in the development of ADHD, there are
several other factors that may influence how the patient responds to the condition.

Prenatal and Perinatal Factors
While genetics and biology are the ultimate contributors to ADHD, other
environmental and social factors are studied to see how they contribute. Prenatal refers to
the time period of a fetus between conception and before birth, or during pregnancy.
Perinatal refers to the time period a few weeks before birth, during birth, and a few weeks
after birth. During the prenatal and perinatal time frame there are a number of events that
may occur to increase ADHD-like symptoms (McGough, 2014).
Prenatal conditions including maternal cigarette consumption, lead, pesticides, and
maternal alcohol abuse and dependence may aggravate ADHD symptoms (Brown, 2013).
These conditions in prenatal and perinatal terms can have an effect on the already
sensitive brain conditions of an ADHD patient (Hinshaw, 2016). Children with mothers
that abused alcohol during pregnancy are twice as likely to develop ADHD, and children
with mothers who are dependent on alcohol during pregnancy are three times as likely to
develop ADHD like symptoms (Banerjee, 2007). It is important to note that many of the
mothers in this study also had ADHD, so it is hard to tell whether the environment or
genetics increased the risk of childhood ADHD development; many studies are trying to
study which of the factors are playing a higher role (McGough, 2014).
Perinatal conditions such as toxemia, eclampsia, maternal age and health, and
duration of labor may also play a role in increased ADHD risk (Brown, 2013). Halmoy,
et al (2012) studied a population of adults with ADHD and proved that low birth weight
and preterm birth increased the risk of ADHD and the lack of executive functions.
Perinatal conditions are often associated with increased developmental disorders and that
is why ADHD may appear more common in these births as it is a developmental disorder.

Psychosocial Risks
Psychosocial refers to the interaction between social factors and thought and
behavior. A famous study by Rutter, et al. (1975) stated that there are six factors that are
associated with increased risk of psychiatric disabilities with pediatric patients: marital
discord, low social status, large family size, paternal criminality, maternal mental
disorder, and foster placement. It is important to emphasize that social factors do not
cause ADHD, however, they play a role in how severe the condition becomes and how
well the patient develops (McGough, 2014). Typically, the presence of one of these
factors will not increase the severity of the condition, but the accumulation of two or
more factors usually results in an increased negative effect on the pediatric ADHD
patient (Rutter, 1975).
“Authoritative parenting” is a combination of firm consequences, warmth,
independence, and guidance. ADHD patients that are under this kind of parenting thrive
the best. Children that live in the above mentioned conditions are often not in a
environment where authoritative parenting is practiced, and that is why the conditions
listed in Rutter et al. (1975) are the most common for negative impacts in ADHD
children. Parents that are arguing with the child or others, are not active in the child’s life,
and are not focused on the needs of the condition are more likely to lead to the increase of
the child’s symptoms (Hinshaw, 2016). While social status is not a cause of ADHD, it is
definitely a strong indicator of the success the patient will have in combating the
disability.

Environmental Risks
Environmental factors that may contribute to ADHD are very broad. Some of the
most controversial factors include lead in water, academic settings, and diet.
Lead in water has often been associated with ADHD symptoms, however not all
patients with ADHD have been exposed to lead and only a small amount of patients that
have been exposed to lead have ADHD. Patients that have been exposed to lead usually
have other risk factors associated with ADHD including low socio-economic status, low
paternal education levels, and poverty. Studies are continuing in this area (Nigg, J.T,
2010).
Many people promote the belief that diet has an effect on causing or and promoting
symptoms of ADHD. There have been many studies revolving around sugar intake and
ADHD, and none have concluded any significant correlation between the two (Bader,
2012). Caffeine is another food component that may increase the attention in ADHD
patients; there are no negligible effects (Leon, 2000). The only component in foods that
has been proven to have an effect on ADHD patients is food coloring, especially Yellow
No. 5. However, it has not been proven if specific characteristics and genotypes in a
person are necessary for food coloring to have an effect on (Nigg, 2012). The studies
involved in diet and ADHD have only been conducted with small samples in certain
areas; further testing is necessary to confirm a precise conclusion.
Gene-Environmental Interactions and Risks
Gene-environmental interactions are offered by an integrated viewpoint that has
emerged with hopes to portray how the environment has an effect on increasing the
symptoms of ADHD that are caused by biology. In this perspective biology causes

ADHD and the environment fuels or depresses the disorder (Nigg, J., 2010). Some
proponents of this interaction believe that adversity in the environment triggers the genes
in a patient to firmly express ADHD characteristics (McGough, 2014).
Several studies discuss how food additives, such as colors, may only increase risk
for patients that have or do no have certain genes. Similarly, studies have shown that
maternal smoking only increases ADHD risk when certain alleles are present (Farone,
2010). These are just a few examples of how the environment-gene model works in
application with ADHD patients.
Diagnosis and Assessment of ADHD in Children
ADHD is a clinically diagnosed disorder. The diagnostic criteria for ADHD is out
in detail in the Diagnostic and Statistical Manual for Mental Disorders (fifth edition,
DSM-5). The DSM-5 is the appropriate guide that physicians should consult during
diagnosis of a mental disorder such as ADHD.The DSM-5 focuses on diagnosis through
evaluation and assessment of the age appropriateness of inattention, hyperactivity, and
impulsivity (McGough, 2014).
The DSM-II viewed ADHD as a hyperkinetic disorder that usually vanished by
adolescence. The DSM-III was the first DSM to list a set of symptoms as a guideline
broken up into hyperactivity, inattention, and impulsivity; in order to be diagnosed with
ADHD a child must have had three of five inattention symptoms, three of six impulsive
symptoms, and two of six hyperactive symptoms (McGough, 2014). The DMS-IV
introduced 18 symptoms, 9 inattentive and 9 hyperactive/inattentive.
The DSM-5 is the current manual that physicians use to diagnose a patient with
ADHD. There have been several changes to the DSM-5 from the DSM-IV. First of all,

ADHD is no longer listed as a disruptive behavioral disorder, showing the changing view
of the disorder. While the DSM-IV states that symptoms must show by age seven, the
DSM-5 states that the symptoms may show as late as age twelve. Other changes of note
includes wording to promote the fluidity of the disorder, changes in subtypes of ADHD,
and impairment is no longer a necessity for diagnosis (Adler, 2015).
The DSM-5 retains the 18 symptoms in the DSM-IV (Table 1). According to the
DSM-5, a patient must exhibit 6 of the 9 symptoms for inattention (Table 1) and/or 6 of
the 9 symptoms for hyperactivity-impulsivity (Table 2) for pediatric patients 16 and
under, and 5 of the 9 for one or both groups if 17 and older (McGough, 2014). In addition
to the symptom conditions, the condition must have an onset before age 12, the
symptoms must be present in two or more settings, the symptoms must have a clear
impact on the function of the individual, and the symptoms must not be better explained
by another mental disorder (Adler, 2015).
A child is usually assessed by a medical professional if ADHD is suspected. Usually
children exhibit symptoms during preschool or early grade school. Often teachers are the
first ones to notice ADHD- like symptoms and recommend treatment be sought. If
children do not exhibit ADHD signs and symptoms by elementary, they should by middle
school due to the increase in workload and their inability to focus on the tasks in class.
Most often, parents take their children to pediatricians to be diagnosed, most of which are
not trained in mental illness and are quick to prescribe prescription drugs before behavior
therapy (Hinshaw, 2016).
A critical part in diagnosing pediatric ADHD patients is the involvement of all or
most systems the child is involved in. Usually the child, parent(s), teacher(s), and other

third parties such as coaches are involved in providing information to the medical
professional assigned to the case, allowing the doctor to make an informed decision.
Before an assessment is scheduled the doctor usually sends out questionnaires, in the
form of rating scales, for everyone to rate the performance of the child for specific tasks
(McGough, 2014). These questions will provide the best insight for the physician to make
a correct diagnosis, however it is important that he take care if the questionnaires differ in
opinion. Parents, teachers, and other parties may have bias;for example, a teacher may
prefer ADHD medications for a child, simply to improve classroom grades (Nass, 2005).
On the day of the assessment a medical professional meets with the child and
usually the parents. The sad truth is that most of these visits last 10-15 minutes, where the
physician analyzes the data, makes a diagnosis, and then prescribes medication or other
treatment. The assessments from third parties are collected and the physician takes time
to interview the parents and the child more thoroughly according to the DSM-5
guidelines. Sometimes doctors have computerized or physical behavioral tests in place to
observe the actions of the child. A medical assessment is done in this visit as well, even
if a non-medical professional is conducting the diagnosis. A basic health physical is
conducted, family information is collected, and previous medical history is taken as well.
These procedures are set in place due to the high risk of cardiovascular issues and risks
that arise when a pediatric patient is placed on stimulant medications for ADHD
(McGough, 2014).
Planning of treatment
Treatment plans for ADHD patients are specific and focus on the individual needs of
the patients. The optimal treatment for pediatric ADHD patients is a combination of
medications behavior and family therapy and counseling, and classroom management.

ADHD medications were originally introduced for use only when behavior management
fails or needs a supplement (Moghadam, 2006). The famous Multimodal Treatment
Study of ADHD (MTA) proved that medications lessened symptoms of ADHD but did
not improve functionality quality of the patient like behavior therapy and counseling did
(Murphy,2005). The emphasis of this paper is to focus on prescription medication use in
the Appalachian region as it pertains to ADHD patients, however a discussion of
alternative therapies is necessary to understanding all of the therapy options that can be
utilized in addition to medications in the Appalachian area.
When a doctor is deciding the correct treatment plan for a ADHD child, the severity
of the case and the individual needs of the patient are deciding factors. Treatment of
ADHD is a very personal plan and no two patients are the same. Most experts agree that
pharmacotherapy should only be considered in cases where behavior therapy cannot be
the only source of treatment. However, most patients are placed on medications of some
kind. The type of medication selected should be based on severity, age, comorbidities,
and reception of medication. It is common for medication to be a go to source of
treatment, however no physician should ever believe that medication treatment should be
the only source of treatment in pediatric patients (McGough, 2014). All patients and
guardians should be in constant contact with a physician and school personnel to monitor
treatment and behavior no matter the treatment plan.
Family focused interventions include parent and child therapy counseling sessions.
These sessions aim to eliminate barriers to effective parenting. This type of counseling is
beneficial to those that are facing stressors in the family home. These sessions are
organized into 1-2 sessions for an hour or two a week, and they can be in multiple

settings, individually or in groups. The counselor focuses on teaching the parents how to
care for a child with ADHD, and emphasis is placed on relationships, structure,
consistency, and health (Forehand, 2013). A more specific type of family intervention is
called parent child interaction training (PCIT). This type of counseling focuses on
teaching parents with younger ADHD patients how to build lasting relationships early on
in the child’s life (Charach, 2013).
Another method of behavior therapy for ADHD patients is school-focused
interventions. Management of ADHD should be carried over into the classroom through
proper classroom placement. The Federal Rehabilitation Act of 1973 states in section 504
that students with mental or physical limitations can receive modifications in the
classroom such as preferred seating and extended times on tests to accommodate for the
disability (Semrud-Clikeman, 2011). Usually 504 modifications are only given to severe
ADHD patients, as a diagnosis alone is not sufficient to gain 504 plans until extensive
counseling is completed and the school approves. Most ADHD students can gain
behavioral classroom management, which is similar to the home intervention in style and
content. This type of management depends on the cooperation of the teacher. Most plans
utilize daily report cards and appropriate consequences and limitations in the child’s daily
routine (Pelham, 2008).

1

Often fails to give close attention to details or makes careless mistakes in
schoolwork, at work, or with other activities.
2
Often has trouble holding attention on tasks or play activities.
3
Often does not seem to listen when spoken to directly
4
Often does not follow through on instructions and fails to finish schoolwork,
chores, or duties in the workplace (e.g., loses focus, side-tracked).
5
Often has trouble organizing tasks and activities.
6
Often avoids, dislikes, or is reluctant to do tasks that require mental effort over a
long period of time (such as schoolwork or homework).
7
Often loses things necessary for tasks and activities (e.g. school materials,
pencils, books, tools, wallets, keys, paperwork, eyeglasses, mobile telephones).
8
Is often easily distracted
9
Is often forgetful in daily activities.
Table 1. Inattentive Symptoms of ADHD described in the DSM-5 for diagnostic
purposes
Note. Adapted from ADHD, p. 29, by J. McGough, 2014, Oxford American psychiatry
library.

1
2
3
4
5

Often fidgets with or taps hands or feet, or squirms in seat.
Often leaves seat in situations when remaining seated is expected.
Often runs about or climbs in situations where it is not appropriate (adolescents
or adults may be limited to feeling restless).
Often unable to play or take part in leisure activities quietly.
Is often "on the go" acting as if "driven by a motor"

6
Often talks excessively.
7
Often blurts out an answer before a question has been completed
8
Often has trouble waiting his/her turn.
9
Often interrupts or intrudes on others (e.g., butts into conversations or games)
Table 2. Hyperactive/impulsive behavior Symptoms of ADHD described in the DSM-5
for diagnostic purposes
Note. Adapted from ADHD, p. 29, by J. McGough, 2014, Oxford American psychiatry
library.
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Overview of ADHD Medications in Pediatric Patients

Stimulant Medications
Psychostimulant medications are the most effective type of medication prescribed to
ADHD patients (Adler, 2015). In fact, 70% of ADHD patients taking stimulants, respond
and prefer stimulant medication to other forms of ADHD treatment (McGough, 2014).
Psychostimulants are psychopharmacological agents used to enhance behavioral and
cognitive functions by stimulating the central nervous system (CNS). Most stimulants are
called “amphetamine-like agents” because they are similar to dopamine and
noradrenaline, two neurotransmitters that contain amine groups (Gerlach, 2014). While
there are several types of stimulant medications available, there are two main
classifications of stimulants in ADHD treatment; methylphenidates and amphetamines.
In order to understand the physiological mechanism behind psychostimulants, one
must understand basic nervous system anatomy and physiology. The central nervous
system is composed of the brain and the spinal cord. The brain and the spinal cord are
made of neurons, or nerve cells. A neuron has a cell body, which contains mostly
cytoplasm and neurotransmitters, an axon, which is an elongated area of the cell which
transports signals to and from the neuron cell body, and dendrites, which serve to sense
the environment and tell the cell body to produce a signal along the axon to other
neurons. An electrical signal is transported along the axons of neurons to the brain where
the signal leads to a response. Signals are passed from neuron to neuron through a
structure called a synapse. Most synapse structures are formed where the end of one
neuron’s axon and the dendrites of another neuron meet. Chemical messengers, called
neurotransmitters, are released into the synapse by the pre-synaptic neuron and received
by the post-synaptic neuron allowing the signal to continue. There are several types of

neurotransmitters, but some commonly known ones include dopamine, norepinephrine,
and epinephrine.
There are several adverse effects that may occur with the use of stimulant
medication. The most common effect is loss of appetite, but other effects include
dizziness, nausea, dry mouth, tics, and cardiovascular issues (McGough, 2014). The use
of stimulant medication neither increases nor decreases the likelihood of abuse (Wilens,
2003). Stimulants are most likely to be abused by college students to increase cognitive
abilities, not pleasure; 5% of college students have reported abuse of stimulants
(McCabe, 2005).
Methylphenidates
Methylphenidates(MPH) were first produced in 1944 as a lethargy and depression
drug. Currently they are one of the most common drugs prescribed for ADHD patients
(Barceloux, 2012). MPHs are psychostimulants and act upon the central nervous system
to increase activity in the prefrontal cortex of the brain, which is associated with
regulating attention, behavior, and cognition. There is one main mechanism of action
associated with MPHs. In the neurological synapse of neurons in the brain, there are
transporters that release and take up neurotransmitters from the synapse. One of these
transporters is the dopamine transporter (DAT), a transporter that reuptakes dopamine
from the synapse into the cytosol of the neuron. When MPHs enter the synapse, they
compete with dopamine for binding onto DATs. This creates competition and because
MPHs have a higher affinity to the DATs, dopamine reuptake is inhibited. This creates a
high concentration of dopamine in the synaptic cleft. The increase of dopamine in the
synapse creates an increase in dopaminergic neurotransmission increasing the activity in

the prefrontal cortex of the brain (Barceloux, 2012). This, in turn, promotes increased
focus and good behavior in ADHD patients.
Methylphenidates are prescribed as tablets, chewable tablets, and oral solutions.
Most commonly MPHs are prescribed as immediate effect dosages, meaning the effects
will be seen at greatest capacity within 3-5 hours. There are extended release (ER) MPHs
as well, that can provide a lasting effect for 10-12 hours after taken. In addition to
common tablets, there are beaded preparations that allow a parent to sprinkle the beads
over a child’s food for ingestion (Adler, 2015). The FDA recommends a maximum dose
of 60 mg/day for immediate release forms and 72 mg/day for ER forms. First time
patients usually begin on a low dosage of 2.5mg to 5mg and then brought up to a target
dose of 0.6 to 2 mg/kg. For pediatric patients it is recommended that medication only be
taken once daily, usually in the morning, but this can vary based on social and academic
needs (Pliszka, 2007). Pediatric patients must also be evaluated frequently for dosage
changes. Many times children are placed on more abrasive medications, when the issue is
they have outgrown the recommended dosage for their weight. Methylphenidates have a
low tolerance and often require a high dosage adjustment (Wilens, 2005). There are
several MPH brand name drugs available including Ritalin, Concerta, Metadate ER,
Methylin, and Daytrana. The only differences amongst these are the names, dosage, and
release mechanisms (Adler, 2015).
Amphetamines
Amphetamines (AMPHs) have been around for hundreds of years. It was not until
the 20th Century that amphetamines became commercially available and popularity
spread. In 1929 biochemist Gordon Alles developed a formula for amphetamine. He

utilized his formula to develop a Benzedrine Inhaler for congestion. The inhaler was
widely popular, but in 1959 the FDA required a prescription for sale due to mounting
abuse (Adamec, 2011). Amphetamines are widely popular drugs for treating symptoms
of ADHD. The chemical structure of AMPHs varies, which is why there are several
variants. AMPHs have a general chemical structure of a phenethylamine core with
methyl groups in the alpha position. Substitutions of the groups on the phenyl core is
what creates many types of AMPHs, and often there is a mixture of AMPHs in an ADHD
medication (Rincon, 2012) AMPHs are a group of psychostimulants that act on the
central nervous system. They increase the amount of dopamine, norepinephrine, and
serotonin in the brain. They have a similar mechanism of action to MPHs and act by
inhibiting monoamine transporters such as DAT, serotonin transporters, and
norepinephrine transporters. (Rincon, 2012)
Amphetamines are prescribed in tablet and capsule forms. They are considered a
Schedule II drug due to the high risk of abuse and addiction. The absorption of AMPHs is
usually rapid with a peak plasma level usually seen three hours after the medication is
taken (Patrick). There are forms of AMPHs in ER form prolonging the effects of the
medications and creating a peak blood plasma concentration after seven hours after
taking the medication (Millichap, 2011). However, it is not recommended to prescribe
ER and long lasting AMPHs to children under the age of six (Gerlach, 2014). For first
time patients, a low dose of 2.5mg to 5mg is started and then brought up to 0.3 to 1
mg/kg a day. As stated above with MPHs, a single daily dose is recommended, but
multiple doses can be administered up to 40mg a day. There are several AMPH brand
name drugs available including Adderall and Adderall XR (mixed amphetamines and

dextroamphetamines), Dexedrine and Spansule (D-amphetamines), Vyvanse
(Lisdexamphetamine dimesylate), and Desoxyn (D-methamphetamine).

Non-Stimulant Medications
Non-stimulant medications are prescribed to pediatric ADHD patients as a second or
third line drug. If stimulants appear to produce comorbidities, if a risk of abuse is present,
or if a response is not seen, non-stimulant medications may be used as a monotherapy or
combined with stimulants to produce a more refined response (Adler, 2015). While nonstimulants are generally not as effective, many patients do report increased attention
spans. There are two main types of non-stimulant medications that are prescribed to
pediatric ADHD patients, norepinephrine reuptake inhibitors and alpha-2 agonists.
Norepinephrine Reuptake Inhibitors
Norepinephrine reuptake inhibitors (NRIs) are a class of drugs that act on the
norepinephrine transporter in the prefrontal cortex of the brain. NRIs are second line
drugs in the treatment of ADHD. They are prescribed when the patient experiences
comorbid tics and, or abuse. NRIs prevent the reuptake of NE into the synapse, thus
increasing the concentration in the synaptic cleft allowing for more connections and
increased focus and behavior (Gerlach, 2014). While MPHs bind better to DATs, NRIs
do not affect the dopaminergic pathway. Because there is not much dopamine present, the
potential for abuse is low since high dopamine levels trigger the reward system of the
brain promoting abuse (Gozal, 2005).
Norepinephrine reuptake inhibitors are prescribed in tablet and capsule forms
mainly. They are not considered a Schedule II drug since the potential for abuse is low.

The absorption of NRIs is rapid with a peak plasma concentration level occurring 1-2
hours after taking the medications. The dosage is weight dependent. Most pediatric
patients start at a dose of 0.5mg/kg/ day for the first week, and then work up to the target
dose of 1.2mg/kg/day (Adler, 2015). It is recommended to give the medication with food
to offset nausea, if necessary. Also, if drowsiness occurs, it is suggested to give the
medication at night (Gerlach, 2014). One of the most popular NRIs is Strattera, or generic
Atomoxetine (ATMX). Strattera is available in capsules of 10,18, 25,40, 60, and 100 mg
(Adler, 2015).
Overall, NRIs are slightly less effective than MPH (Newcorn, 2008), and are
significantly less effective than AMPHs (Wigal, 2005). NRIs should still be considered a
first line drug for patients who suffer from adverse effects of stimulants(Wigal, 2005).
Improvement is generally seen starting around 4 weeks after NRIs are started in a patient,
with the full effects displayed in 6-8 weeks. There are several potential adverse effects
such as insomnia, irritability, mood swings, and suicidal thoughts (Adler, 2015).
Alpha-2 Agonists
Alpha-2 agonists are the second main type of non-stimulant medication used to
combat ADHD. Like NRIs, alpha-2 agonists are considered a second line drug for normal
ADHD patients, but a first line drug for ADHD patients that experience abuse and
comorbid tics. Alpha-2 agonists were originally developed as antihypertensive
medications, and thus are given to patients that may have high blood pressure as well
(Millichap, 2011).
An adrenergic alpha- agonist is an agent that stimulates the alpha adrenergic
receptors. Adrenergic receptors are receptors that receive signals from neurotransmitters

such as norepinephrine and epinephrine, and then signal to produce a response. The
binding of norepinephrine or epinephrine will usually trigger a flight-or-fight response.
There are two subtypes of adrenergic receptors, alpha and beta. The alpha subtype is
broken down into two more types, alpha-1 and alpha-2. While alpha-1 receptors are
found in smooth tissue, alpha-2 receptors are mostly found in the pancreas and
neurological synapses. Alpha-2 receptors, when stimulated with norepinephrine and
epinephrine, will inhibit the release of more norepinephrine and epinephrine through a
mechanism called feedback inhibition(Sinclair, 2003). Alpha-2 agonists mimic the
actions of norepinephrine and epinephrine and fool the body into thinking the levels are
actually higher than they really are. The body then decreases the amount of
norepinephrine and epinephrine released into synapses, thus creating the sedative effects
that alpha-2 agonists are associated with (Bidwell, 2010). It might seem strange that a
sedative effect would improve ADHD symptoms for a patient. The exact mechanism in
which alpha-2 agonists aid ADHD patients is not fully understood, but it is believed that
low levels of norepinephrine and epinephrine caused by the agonists have a calming and
sedative effect on patients, providing them with improved focus and less hyperactivity
(Banaschewski, 2004).
One type of alpha-2 agonist is clonidine. Clonidine is manufactured in two main
forms, immediate release (CIR) and extended release (CXR). The immediate release form
only has an effect for three to six hours, while the extended release form is released over
a twelve hour period. The extended release form of clonidine has been proven to lessen
the possibility of adverse effects. CIR is made in 0.1, 0.2, and 0.3mg tablets and CXR is
made in 0.1 or 0.2mg tablets (Adler,2015). Pediatric patients are most often prescribed

CXR, as the CIR is associated with adverse effects such as dry mouth and increased
sedation. Patients are started on a smaller dose of 0.1mg/day at bedtime, and then brought
up to a target dosage around 0.2mg/ day (Gerlach, 2014). Improvement for patients
utilizing this drug is usually seen two weeks after the medication is begun (Jain, 2011).
Clonidine has been proven as an effective drug in several studies (Jain, 2011) and is also
proven to be effective as an adjunctive treatment with stimulant medications (Kollins,
2011). There are several adverse effects that may occur when taking this medication.
Increased fatigue and sedation, headaches, dizziness, dehydration, dry mouth, and blood
pressure oscillations are just a few of the risks (Adler, 2015). Patients should not stop
taking clonidine abruptly due to the possibility of blood pressure elevation, headaches
and tics. If a patient needs to stop taking clonidine, a gradual weaning over 4-7 days
should occur (Millichap, 2011).
Another alpha-2 agonist used to treat ADHD is guanfacine. The main difference
between guanfacine and clonidine is that guanfacine is more specific for alpha-2A
receptor subtype (Gerlach, 2014). Guanfacine is also less potent than clonidine, however
this is accounted for in the dosage (Adler, 2015). Guanfacine is also manufactured in
immediate and extended release forms, and the two are not interchangeable. GIR is made
in 1 and 2mg tablets and GXR is made in 1,2,3, and 4 mg tablets. Pediatric patients are
usually given GXR and are started on a dose of 1mg/day. This is increased gradually up
to 4mg/ day (Gerlach, 2014). Improvement is usually seen in patients between two and
four weeks after treatment is started (Jain, 2011). Guanfacine is generally effective in
treating hypertensive pediatric patients, although it is still significantly less effective than
MPHs. It is also proven to be more effective for some patients when guanfacine is used in

conjunction with MPHs (Spencer, 2009). The adverse effects are similar to clonidine,
and include cardiovascular problems, dry mouth, dizziness, and sedation, although dry
mouth and sedation are usually less likely with guanfacine. Just like clonidine,
guanfacine should not be suddenly discontinued, as withdrawal and cardiovascular
complications may arise (Gerlach, 2014).
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Limitations, Proposed Methods, and Expected Results.

Several limitations occurred that prevented this study from being a complete report.
The inability to gain access to de-identified personal health information from a local
pharmacy was the main limitation. A lack of response created a situation in which the
research could not be completed. The goals of this study will be outlined in detail so that
they may be completed at a later time.
First, de-identified PHI for pediatric patients on ADHD medication was to be
collected from a local independent pharmacy that had three separate locations in vastly
different areas of town. A whole year of PHI would have been requested for all patients
from each location that are prescribed any of the stimulant and non-stimulant ADHD
medications discussed in prior sections. The PHI would have been de-identified before
collection. The PHI ideally would have replaced the patient’s name with a number in a
manner that the patient could not be re-identified. In addition to the patient’s name,
address, prescribers, and any additional medical information could not be accessed. The
only information included on the PHI would have been the medication name, number of
scripts written for that medication, the number of times the medication was received by
the patient, and the dates the medication was received. If possible, the birthday of the
patient would have been collected so that age of the pediatric patient could be included in
data analysis.
As stated, the pharmacies were located in three different areas of town. After PHI
collection, analysis of each of the pharmacy locations would have occurred. Several
websites are available for this information. The Appalachian Regional Commission has
data available for personal income, education, unemployment, and poverty for each
county and state in the Appalachian region, including Tennessee and Knox County. In

addition, the Center for Disease Control (CDC) also offers many data sheets specifically
for ADHD. These sheets show data for medication and treatment plans for ADHD
patients in the state of Tennessee as a whole and by region.
The preferred website for use in this study comes from the Online Analysis and
Statistical Information System. This is a website devoted to showing health statistics for
specific regions. The Social Impact Mapper is an interactive map that shows
socioeconomic status and demographics for neighborhoods. It is designed to be used to
highlight health disparities and issues. This interactive map allows users the ability to
select certain demographics and ranges and the site will highlight the regions that meet
the specifications made by the user. Demographics can be changed so that income,
poverty, education, single parent household percentages, age, race, and gender can be
shown for a specific range. For example, if a user wants to choose an area with a low
income, an income range can be selected and the map will highlight areas that have a low
income in the range selected.
These resources would have been used to collect information including race, gender,
income level, education levels, and poverty, among others, for the people living in
neighborhoods surrounding the three pharmacy locations. Information about schools and
health institutions in the area surrounding each pharmacy would have also been collected.
This data would have then been compared to the PHI data with the purpose to show any
correlations between the demographics of the pharmacy location and the patients at that
pharmacy. Because each pharmacy was in a different area of Knoxville, it was expected
that each location would have a significant difference in patients and demographics of the

area. Results may have shown that specific demographics correlate to trends in ADHD
medication usage and prescriptions.
Several assumptions would have been made with this approach, including one that
the patients receiving medication from the pharmacy presumably should live in the area
around the pharmacy’s location. Also, it assumes that the patient is in a certain socioeconomic status based on the location of the pharmacy and the neighborhoods
surrounding it. In addition, it assumes that the patients coming to the pharmacies in the
study are representative of the whole Knoxville population. Lastly, the study does not
take into account any personal reasoning behind receiving medications and alternative
therapy the patient may be receiving. These assumptions were made based on the nature
of the de-identified PHI. If this study were to be completed in a widespread manner, more
than three pharmacies should be included to assure that the entire population of Knoxville
is accounted for. Also, approval should be sought for a study that may include more
patient information to assure that the patient is associated with correct demographics.
Perhaps funding and approval should be gained so that large retail pharmacies that are
located in more areas throughout town may be able to participate.
This study hoped to find a correlation between ADHD patients, their medication,
and certain demographics such as race, socio-economic status, income level, and
education among others. It also aimed to show trends in ADHD medication reception
over a typical year so that medications given during time in school and time out of school
could be analyzed. The data provided could then be used to create plans for enhancing
ADHD patient diagnosis, treatment, and medication therapy management.
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Discussion
In the United States 3%-10% of children have been diagnosed with Attention Deficit
Hyperactive Disorder (McGough, 2014). Western states have a significantly lower rate of
ADHD diagnoses than southern and Midwest states. Many southern states have rates of
ADHD diagnoses as high as 15% or greater. The same is true for rates of medication for
pediatric patients. An ADHD patient in the south is twice as likely as an ADHD patient in
California to receive medication for ADHD (Hinshaw, 2016). Many of the southern states
that have high rates of diagnoses and medication rates are Appalachian states, and the
state of Tennessee is referenced often as having some of the highest rates of ADHD
diagnoses in the country.
It is apparent that ADHD has been embraced by the medical community, and thus is
becoming a burden to society, especially in southern Appalachian states. The question
still is why many of the Appalachian states are suffering with the burden of ADHD more
than other states. While studies have shown ADHD is caused by biological sources, the
severity of the disorder often has a lot to do with the social and economic environment
the child is placed in. The Appalachian certainly has a unique culture, socially and
economically, that may contribute to the high rates of diagnoses and medication therapies
being received.
It is important to consider all of the possibilities that may factor into a child being
diagnosed and receiving medications for ADHD. The Appalachian region has many
factors such as school systems with a high focus on testing scores, high unemployment,
poverty, high rates of single parents, and low access to medical care and coverage that
may affect how ADHD is perceived and diagnosed. This study hoped to be able to look at

various social factors in different regions of an Appalachian town to try and uncover the
social and economic factors that create trends in ADHD medications in an Appalachian
town. Unfortunately, limitations prohibited the completion of the study.
ADHD causes a significant burden on the family system as well as educational and
social systems in a ADHD child’s life. Children that have ADHD are more likely to
struggle in school, have other mental disorders in addition to ADHD, and have issues
later in life with gambling, criminal activity, and substance abuse (Kessler, 2006). ADHD
children are also more likely to experience increased emergency room visits and
accidents (McGough, 2014). ADHD can cause an extreme burden on a family that is
lacking an education and steady income to afford sufficient treatment and therapy. Many
Appalachian families are not educated enough to understand the various treatment
options and how to manage a child that has ADHD at home and at school. In addition on
average an ADHD pediatric patient’s parents spend $1,000-$5,000 in medical expenses
for appointments and treatment (Doshi, 2012).
ADHD research is necessary in the Appalachian region for a number of reasons. The
high costs associated with having an ADHD family member, creates a financial burden
on a struggling economic region. Medical costs for a pediatric ADHD patient are three
times more than an average child annually. Pediatric patients that do not manage their
condition mature into adults with ADHD, and usually struggle to maintain employment
to afford treatment (Biederman, 2006). Decreasing the number of ADHD patients in the
region, or even defining treatment to include less expensive medications, would reduce
the cost for many families and create more successful, productive citizens in the
community. Also, gaining support from school systems would be beneficial in creating

curriculums to stimulate the minds of children that struggle with ADHD symptoms; this
may also aid in decreasing the number of failing schools in the Appalachian region.
ADHD patients are at risk for greater criminal activity. Pediatric ADHD patients will on
average spend more time on probation and have higher criminal convictions (Olazagast,
2012). Acknowledging medication trends and crafting behavior therapy plans to
accompany or replace them should be the goals of physicians and pharmacists to decrease
the counts of criminal activity from ADHD patients. It is important to discuss why
ADHD is a problem in the Appalachian region as discussions could promote increasing
educational efficiency, decreasing criminal behaviors, and relieving financial burden on
families and the community.
There is a correlation between ADHD cases and many of the specific social burdens
that Appalachian families experience such as low income, low education levels,
unemployment, and family culture. It is apparent through research and statistics that
ADHD is a problem in the Appalachian region, and the high rates may be caused by the
social and economic issues stemming from the region. Understanding the social factors
that may be causing high trends in ADHD medication treatment and diagnoses in the
Appalachian region is key to developing a medical plan and educational materials to aid
the families financially, emotionally, and physically. It is important to understand that
ADHD patients also have many comorbidities, and through research it may be possible to
focus on behavior therapy rather than medication so that individuals receive a wellrounded treatment that is not set on specific standards. Perhaps, the solution should be to
combat the issues that Appalachian families face, such as poverty and low education,
instead of fighting the high ADHD case rate. It might be that if the social issues of the

Appalachian region were aided then ADHD rates may decrease. However, further
research is necessary to determining an exact cause. By analyzing the areas that are
receiving medication and treatment at a high rate, society can begin to combat the issues
and give aid to groups that need it, so ADHD will not become a societal burden to the
people of Appalachia.
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